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oxidative phosphorylation - the synthesis of ATP using the chemical en-
ergy derived from oxidation of nutrients – and result in widely varying
and tissue-specific manifestations. Being of genetic and inborn etiology,
there are so far no curative therapies. Some of the strategies proposed,
and to some extent tested in animal models and in patients, are phar-
macological modulation of mitochondrial biogenesis and fission/fusion,
and of central cellular pathogenesis-related processes such as apoptosis
and autophagy, and metabolic bypass/supplementation therapies [1].
Intense research activities are ongoing to find and test treatment strat-
egies for these devastating disorders. Valuable models for mechanistic
studies and preclinical trials have been generated by introducing dis-
ease mutations into mice. In this issue, a study testing oral rapamycin
in a mouse model (Coq9R239X) with compromised coenzyme Q (CoQ)
biosynthesis, manifesting as encephalomyopathy, showed no beneficial
effect [2]. This is contradictory to several previous reports that have
shown beneficial effects in mitochondrial disease models [3–8].
Rapamycin is a natural bacterial macrolide metabolite first isolated
from a soil sample from Easter Island (Rapa Nui) in 1972. Initially stud-
ied as an antifungal agent, its immunosuppressive and antiproliferative
properties in mammalian cells were discovered in the 1990s. It
(sirolimus) was approved in USA in 1999 for prophylaxis of rejection
in renal transplantation patients. Rapamycin binds the 12 kDa FK506-
binding protein (FKBP12), and this complex binds and inhibitsmamma-
lian target of rapamycin (mTOR, also known as mechanistic TOR) com-
plex (mTORC) [9]. The mTOR nutrient and growth factor signaling
pathway is amaster regulator of cell growth andmetabolism, and there-
fore implicated in numerous human diseases such as cancer, diabetes,
obesity, neurological diseases, and genetic disorders [9]. In 2013,
based on their earlier molecular studies in yeast, Johnson et al. first pro-
vided evidence thatmTOR signaling can be involved in the pathogenesis
ofmitochondrial diseases [3]. They showed that pharmacological inhibi-
tion of the mTOR1 pathway with both oral [4] and intraperitoneally [3]
injected rapamycin robustly alleviated encephalopathy and increased
survival inNdufs4−/−mice, a model of Leigh syndromewith respiratoryDOI of original article: https://doi.org/10.1016/j.ebiom.2019.03.025.
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have been published ([3–8], Table 1). They show that high doses of
rapamycin have beneficial effects in mitochondrial encephalopathy
[4,6] and skeletal myopathy [5,8]. In a Tk2-H126N knock-in mouse
model of mtDNA depletion syndrome with encephalopathy and myop-
athy, no convincing effect on tissue histopathology was observed upon
mTOR1 inhibition with rapamycin, but the survival of the sick mice
was extended [7]. The “deletor mouse” (carrying a Twinkle helicase
transgene with a dominant patient mutation) presenting with mito-
chondrial myopathy was reported to have changes in several pathways
downstream of mTOR1 (such as folate cycle, serine biosynthesis, FGF21
secretion and fiber-specifically increased S6 phosphorylation) in the af-
fected muscles, thereby indicating rapamycin as a potential treatment.
Indeed, i.p. administration of 8 mg/kg resulted in robust improvement
of muscle function and histology and normalization of mtDNA deletion
load and several other molecular parameters [5]. Likewise, in muscle-
specific Cox15 knockout micewith disrupted respiratory chain complex
IV assembly, despite the lack of clear activation of mTOR1 downstream
pathways, rapamycin stimulated autophagy and biogenesis of lyso-
somes, which the authors suggested resulted in improved muscle his-
tology. However, if rapamycin affected the premature lethality of
these mice was not reported [8].
The present study by Barriocanal-Casado et al. [2] investigated, in
spite of no clear evidence of increased mTOR1 activity in their model,
whether rapamycin has a general beneficial effect in mitochondrial en-
cephalomyopathy. They utilized Coq9R239Xmicewith defective CoQ bio-
synthesis and the two oral dosages used, a low and a high (Table 1),
corresponded to those previously shown efficacious in other models
[4–6]. The outcome measures included survival, motor performance,
brain imaging, tissue histology, and transcriptome and metabolite as-
sessments. Apart from slight improvement in cerebral histopathology,
rapamycin had no effect on any parameters of disease progression.
The low dose resulted in changes of liver metabolites and midbrain
transcriptomics, indicating an effect at molecular level. With the higher
dose, all examined tissues responded to rapamycin as judged by S6 pro-
tein phosphorylation, awidely used and robust indicator ofmTOR activ-
ity. Unexpectedly, the high dose resulted in an adverse effect on the
mice, decreasing their survival. Interestingly, Barriocanal-Casado et al.
did not observe induction of autophagy in any tissue analyzed (brain,
heart, liver, and kidney) despite clear mTORC1 inhibition by the highthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Preclinical rapamycin trials in mouse models of mitochondrial disease (*mTOR1 activation in the mutant verified by analysis of S6 phosphorylation)
Model [reference] Route, dose Survival Histo-pathology Motor
perform.
mTOR act.*/+rapamycin
Ndufs4−/− encephalopathy [3] i.p., 8.0 mg/kg daily or every other day Increased with
daily dose
Improved Improved Increased/decreased
Ndufs4−/− encephalopathy [4] oral, 14, 42, 126 or 378 ppm in chow 14 no effect
42 increased
378 increased
Not reported Not
reported
Not reported
Dominant mutant Twinkle transgene,
myopathy [5]
i.p., 8.0 mg/kg daily Not reported Improved Not
reported
Increased/decreased
Ndufs4−/− encephalopathy [6] oral, 0.5, 8.0, 20 mg/kg 0.5 no effect
8.0 increased
20 increased
Mitochondria
improved (EM)
Improved Not reported/unclear
Tk2-H126N knock-in encephalopathy,
myopathy [7]
oral to dam, 0.8 mg/kg (pregnancy) 4mg/kg
(postnatal)
Increased Unaffected Unaffected Unaffected/unaffected
Skeletal muscle-specific Cox15−/−,
myopathy [8]
i.p., 8.0 mg/kg daily Not reported Improved Improved Unaffected/decreased
Coq9p.R239X encephalopathy [2] oral, 28 or 225 ppm in chow 28 no effect
225 decreased
Slight improvement Unaffected Unaffected/decreased
(high dose)
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of damaged cellular components and their recycling for fuel has been
suggested as a therapeuticmechanism for rapamycin. Clearly, better un-
derstanding of the role of autophagy in the pathogenesis of mitochon-
drial diseases, as well as of the effect of rapamycin on it, is needed.
Moreover, the reliability of themethods to assess autophagy in autopsy
samples is still lacking.
This study is interesting and important firstly because there is a
chronic need to seemorewell-conducted preclinical trialswithnegative
outcomes published. This will fight publication bias that is obviously
common in both preclinical and clinical research. Secondly, it under-
scores that therapeutic targeting of a single pathway, no matter how
central physiologically and how successful in other models, is unlikely
to work for all mitochondrial disorders. The metabolic derangements
in each disordermust first be characterized in detail and thereafter a fo-
cused strategy designed and investigated in sufficiently large experi-
mental groups to enable recording of both beneficial and adverse
events. There will likely not be one drug for the vast spectrum of differ-
ent mitochondrial diseases [10]. Additionally, the drug doses used in
mouse studies raise the question of safety, as they tend to be higher
than those approved for humans.
In summary, it is of utmost importance to publish also the preclinical
studies showing no benefit of a proposed new treatment. Moreover, the
experimental animal groups should be large enough to show biologi-
cally meaningful, statistically robust results. It remains an unanswered
question how many trials showing no benefit of a drug or other inter-
vention have been performed and left unpublished. To ensure accumu-
lation and availability of unbiased evidence we suggest that preclinical
animal studies using drugs already approved for human use – and
thus easier to adopt to clinical trials than novel molecules - should bemandatorily registered in a preclinical database, as is the case for clinical
trials.
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